2020-07262. Pulmonary-Allergy Drugs Advisory Committee; Postponed  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Notice.

    SUMMARY:

    The meeting of the Pulmonary-Allergy Drugs Advisory Committee (PADAC) scheduled for April 21, 2020, is postponed. The Food and Drug Administration (FDA), like other government agencies, is taking the necessary steps to ensure the Agency is prepared to continue our vital public health mission in the event that our day-to-day operations are impacted by the COVID-19 public health emergency. Therefore, we are canceling or postponing all non-essential meetings through the month of April. We will reassess on an ongoing basis for future months. Therefore, this meeting is being postponed. The meeting was announced in the Federal Register on February 20, 2020.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    LaToya Bonner, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, Fax: 301-847-8533, email: PADAC@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area. Please call the Information Line for up-to-date information on this meeting, which was announced in the Federal Register of February 20, 2020 (85 FR 9780).

    Start Signature

    Dated: April 1, 2020.

    Lowell J. Schiller,

    Principal Associate Commissioner for Policy.

    End Signature End Further Info End Preamble

    [FR Doc. 2020-07262 Filed 4-6-20; 8:45 am]

    BILLING CODE 4164-01-P

Document Information

Published:
04/07/2020
Department:
Food and Drug Administration
Entry Type:
Notice
Action:
Notice.
Document Number:
2020-07262
Pages:
19491-19491 (1 pages)
Docket Numbers:
Docket No. FDA-2020-N-0626
PDF File:
2020-07262.Pdf
Supporting Documents:
» Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments
» Pulmonary-Allergy Drugs Advisory Committee; Postponed
» Pulmonary-Allergy Drugs Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments